Background: Derangements of the gut microbiome have been linked to increased systemic inflammation and central nervous system disorders, including schizophrenia. This systematic review thus aimed to investigate the hypothesis that probiotic supplementation improves schizophrenia symptoms. Methods: By using the keywords (probiotic OR gut OR microbiota OR microbiome OR yogurt OR yoghurt OR lactobacillus OR bifidobacterium) AND (schizophrenia OR psychosis), a preliminary search of the PubMed, Medline, Embase, Google Scholar, ClinicalTrials.gov, Clinical Trials Register of the Cochrane Collaboration Depression, Anxiety and Neurosis Group (CCDANTR), and Cochrane Field for Complementary Medicine databases yielded 329 papers published in English between January 1, 1960 and May 1, 2018. Attempts were made to search grey literature as well. Results: Three clinical studies were reviewed, comparing the use of probiotics to placebo controls. Applying per-protocol analysis and a fixed-effects model, there was no significant difference in schizophrenia symptoms between the group that received probiotic supplementation and the placebo group post-intervention as the standardized mean difference was –0.0884 (95% CI –0.380 to 0.204, p = 0.551). Separate analyses were performed to investigate the effect of probiotic supplementation on positive or negative symptoms of schizophrenia alone. In both instances, no significant difference was observed as well. Conclusion: Based on current evidence, limited inferences can be made regarding the efficacy of probiotics in schizophrenia. Although probiotics may have other benefits, for example to regulate bowel movement and ameliorate the metabolic effects of antipsychotic medications, the clinical utility of probiotics in the treatment of schizophrenia patients remains to be validated by future clinical studies.

1.
Saha
S
,
Chant
D
,
Welham
J
,
McGrath
J
.
A systematic review of the prevalence of schizophrenia
.
PLoS Med
.
2005
May
;
2
(
5
):
e141
.
[PubMed]
1549-1277
2.
Knapp
M
,
Mangalore
R
,
Simon
J
.
The global costs of schizophrenia
.
Schizophr Bull
.
2004
;
30
(
2
):
279
93
.
[PubMed]
0586-7614
3.
Cloutier
M
,
Aigbogun
MS
,
Guerin
A
,
Nitulescu
R
,
Ramanakumar
AV
,
Kamat
SA
, et al.
The economic burden of schizophrenia in the United States in 2013
.
J Clin Psychiatry
.
2016
Jun
;
77
(
6
):
764
71
.
[PubMed]
0160-6689
4.
Strauss
JS
,
Carpenter
WT
,
Bartko
JJ
.
Speculations on the processes that underlie schizophrenic symptoms and signs: III
.
Schizophr Bull
.
1974
;
1
(
11
):
61
9
.
[PubMed]
0586-7614
5.
Fusar-Poli
P
,
Papanastasiou
E
,
Stahl
D
,
Rocchetti
M
,
Carpenter
W
,
Shergill
S
, et al.
Treatments of negative symptoms in schizophrenia: meta-analysis of 168 randomized placebo-controlled trials
.
Schizophr Bull
.
2015
Jul
;
41
(
4
):
892
9
.
[PubMed]
0586-7614
6.
Nemani
K
,
Hosseini Ghomi
R
,
McCormick
B
,
Fan
X
.
Schizophrenia and the gut-brain axis
.
Prog Neuropsychopharmacol Biol Psychiatry
.
2015
Jan
;
56
:
155
60
.
[PubMed]
0278-5846
7.
Rogers
GB
,
Keating
DJ
,
Young
RL
,
Wong
ML
,
Licinio
J
,
Wesselingh
S
.
From gut dysbiosis to altered brain function and mental illness: mechanisms and pathways
.
Mol Psychiatry
.
2016
Jun
;
21
(
6
):
738
48
.
[PubMed]
1359-4184
8.
Na
KS
,
Jung
HY
,
Kim
YK
.
The role of pro-inflammatory cytokines in the neuroinflammation and neurogenesis of schizophrenia
.
Prog Neuropsychopharmacol Biol Psychiatry
.
2014
Jan
;
48
:
277
86
.
[PubMed]
0278-5846
9.
Schwarz
E
,
Maukonen
J
,
Hyytiäinen
T
,
Kieseppä
T
,
Orešič
M
,
Sabunciyan
S
, et al.
Analysis of microbiota in first episode psychosis identifies preliminary associations with symptom severity and treatment response
.
Schizophr Res
.
2018
Feb
;
192
:
398
403
.
[PubMed]
0920-9964
10.
Alander
M
,
Satokari
R
,
Korpela
R
,
Saxelin
M
,
Vilpponen-Salmela
T
,
Mattila-Sandholm
T
, et al.
Persistence of colonization of human colonic mucosa by a probiotic strain, Lactobacillus rhamnosus GG, after oral consumption
.
Appl Environ Microbiol
.
1999
Jan
;
65
(
1
):
351
4
.
[PubMed]
0099-2240
11.
Frei
R
,
Akdis
M
,
O’Mahony
L
.
Prebiotics, probiotics, synbiotics, and the immune system: experimental data and clinical evidence
.
Curr Opin Gastroenterol
.
2015
Mar
;
31
(
2
):
153
8
.
[PubMed]
0267-1379
12.
Ng
QX
,
Koh
SS
,
Chan
HW
,
Ho
CY
.
Clinical use of curcumin in depression: A meta-analysis
.
J Am Med Dir Assoc
.
2017
Jun
;
18
(
6
):
503
8
.
[PubMed]
1525-8610
13.
Rondanelli
M
,
Faliva
MA
,
Perna
S
,
Giacosa
A
,
Peroni
G
,
Castellazzi
AM
.
Using probiotics in clinical practice: where are we now? A review of existing meta-analyses
.
Gut Microbes
.
2017
Nov
;
8
(
6
):
521
43
.
[PubMed]
1949-0976
14.
Ng
QX
,
Peters
C
,
Ho
CY
,
Yutong
DL
,
Yeo
WS
.
A meta-analysis of the use of probiotics to alleviate depressive symptoms
.
J Affect Disord
.
2017
.
[PubMed]
0165-0327
15.
Moher
D
,
Liberati
A
,
Tetzlaff
J
,
Altman
DG
;
PRISMA Group
.
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement
.
Ann Intern Med
.
2009
Aug
;
151
(
4
):
264
9
.
[PubMed]
0003-4819
16.
Higgins
JP
,
Altman
DG
,
Gøtzsche
PC
,
Jüni
P
,
Moher
D
,
Oxman
AD
, et al.;
Cochrane Bias Methods Group
;
Cochrane Statistical Methods Group
.
The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials
.
BMJ
.
2011
Oct
;
343
oct18 2
:
d5928
.
[PubMed]
0959-8138
17.
Dickerson
FB
,
Stallings
C
,
Origoni
A
,
Katsafanas
E
,
Savage
CL
,
Schweinfurth
LA
, et al.
Effect of probiotic supplementation on schizophrenia symptoms and association with gastrointestinal functioning: a randomized, placebo-controlled trial
.
Prim Care Companion CNS Disord
.
2014
;
16
(
1
):
PCC.13m01579
.
[PubMed]
2155-7772
18.
Severance
EG
,
Gressitt
KL
,
Stallings
CR
,
Katsafanas
E
,
Schweinfurth
LA
,
Savage
CL
, et al.
Probiotic normalization of Candida albicans in schizophrenia: A randomized, placebo-controlled, longitudinal pilot study
.
Brain Behav Immun
.
2017
May
;
62
:
41
5
.
[PubMed]
0889-1591
19.
Tomasik
,
J.
,
Yolken
,
R.H.
,
Bahn
,
S.
and
Dickerson
,
F.B.
,
2015
.
Immunomodulatory effects of probiotic supplementation in schizophrenia patients: A randomized, placebo-controlled trial.
Biomarker insights, 10, pp.BMI-S22007.
20.
Doron
,
S.
and
Snydman
,
D.R.
,
2015
.
Risk and safety of probiotics.
Clinical Infectious Diseases, 60(suppl_2), pp.S129-S134.
21.
Soh
AY
,
Kang
JY
,
Siah
KT
,
Scarpignato
C
,
Gwee
KA
.
Searching for a definition for pharmacologically refractory constipation: A systematic review
.
J Gastroenterol Hepatol
.
2018
Mar
;
33
(
3
):
564
75
.
[PubMed]
0815-9319
22.
Sayon-Orea
C
,
Martínez-González
MA
,
Ruiz-Canela
M
,
Bes-Rastrollo
M
.
Associations between Yogurt Consumption and Weight Gain and Risk of Obesity and Metabolic Syndrome: A Systematic Review
.
Adv Nutr
.
2017
Jan
;
8
(
1
):
146S
54S
.
[PubMed]
2161-8313
23.
Mattson
MP
,
Maudsley
S
,
Martin
B
.
BDNF and 5-HT: a dynamic duo in age-related neuronal plasticity and neurodegenerative disorders
.
Trends Neurosci
.
2004
Oct
;
27
(
10
):
589
94
.
[PubMed]
0166-2236
24.
Durany
N
,
Michel
T
,
Zöchling
R
,
Boissl
KW
,
Cruz-Sánchez
FF
,
Riederer
P
, et al.
Brain-derived neurotrophic factor and neurotrophin 3 in schizophrenic psychoses
.
Schizophr Res
.
2001
Oct
;
52
(
1-2
):
79
86
.
[PubMed]
0920-9964
25.
Hope
S
,
Ueland
T
,
Steen
NE
,
Dieset
I
,
Lorentzen
S
,
Berg
AO
, et al.
Interleukin 1 receptor antagonist and soluble tumor necrosis factor receptor 1 are associated with general severity and psychotic symptoms in schizophrenia and bipolar disorder
.
Schizophr Res
.
2013
Apr
;
145
(
1-3
):
36
42
.
[PubMed]
0920-9964
26.
van Kesteren
CF
,
Gremmels
H
,
de Witte
LD
,
Hol
EM
,
Van Gool
AR
,
Falkai
PG
, et al.
Immune involvement in the pathogenesis of schizophrenia: a meta-analysis on postmortem brain studies
.
Transl Psychiatry
.
2017
Mar
;
7
(
3
):
e1075
.
[PubMed]
2158-3188
27.
Kemgang
TS
,
Kapila
S
,
Shanmugam
VP
,
Kapila
R
.
Cross-talk between probiotic lactobacilli and host immune system
.
J Appl Microbiol
.
2014
Aug
;
117
(
2
):
303
19
.
[PubMed]
1364-5072
28.
Yano
JM
,
Yu
K
,
Donaldson
GP
,
Shastri
GG
,
Ann
P
,
Ma
L
, et al.
Indigenous bacteria from the gut microbiota regulate host serotonin biosynthesis
.
Cell
.
2015
Apr
;
161
(
2
):
264
76
.
[PubMed]
0092-8674
29.
Barrett
E
,
Ross
RP
,
O’Toole
PW
,
Fitzgerald
GF
,
Stanton
C
.
γ-Aminobutyric acid production by culturable bacteria from the human intestine
.
J Appl Microbiol
.
2012
Aug
;
113
(
2
):
411
7
.
[PubMed]
1364-5072
30.
Du
C
,
Zhang
B
,
He
Y
,
Hu
C
,
Ng
QX
,
Zhang
H
, et al.
Biological effect of aqueous C60 aggregates on Scenedesmus obliquus revealed by transcriptomics and non-targeted metabolomics
.
J Hazard Mater
.
2017
Feb
;
324
Pt B
:
221
9
.
[PubMed]
0304-3894
31.
McFarland
LV
,
Evans
CT
,
Goldstein
EJ
.
Strain-Specificity and Disease-Specificity of Probiotic Efficacy: A Systematic Review and Meta-Analysis
.
Front Med (Lausanne)
.
2018
May
;
5
:
124
.
[PubMed]
2296-858X
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.